RT Journal Article
SR Electronic
T1 Single-Domain Antibody Theranostics on the Horizon
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1475
OP 1479
DO 10.2967/jnumed.122.263907
VO 63
IS 10
A1 Wei, Weijun
A1 Younis, Muhsin H.
A1 Lan, Xiaoli
A1 Liu, Jianjun
A1 Cai, Weibo
YR 2022
UL http://jnm.snmjournals.org/content/63/10/1475.abstract
AB Single-domain antibody (sdAb) is among the most promising vectors for developing molecular imaging tracers. Several sdAb tracers targeting human epidermal growth factor receptor 2 or programmed death ligand 1 have entered clinical practice. However, radiolabeled single-valent sdAbs generally have high kidney retention, limiting their therapeutic applications. Therefore, engineering strategies such as PEGylation or incorporation of renal cleavable linkers can be adapted to improve pharmacokinetics and reduce kidney retention. In this Focus on Molecular Imaging review, we try to summarize the latest developments in sdAb-derived agents and propose potential strategies that can be used to improve the theranostic value of radiolabeled sdAbs.